Biomoda to report lung cancer diagnostic trial results in early 2010
This article was originally published in Clinica
Executive Summary
Biomoda has completed recruitment in a phase II study of its early-stage diagnostic for lung cancer, CyPath. The trial, which has enrolled over 500 patients with a history of heavy smoking, will now start analysing samples from already-diagnosed lung cancer patients. The Albuquerque, New Mexico company expects to have final data in the first half of 2010. CyPath is based on a patented porphyrin-based compound that binds to cancer cells and fluoresces red under ultraviolet light. It is designed for routine screening of large populations. In the study, deep-lung sputum samples will be screened using both CyPath and traditional Pap staining, and patients will also have a CT scan – the current standard of care for lung cancer detection.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.